246 related articles for article (PubMed ID: 24608633)
1. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of axitinib.
Chen Y; Tortorici MA; Garrett M; Hee B; Klamerus KJ; Pithavala YK
Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
Ling J; Johnson KA; Miao Z; Rakhit A; Pantze MP; Hamilton M; Lum BL; Prakash C
Drug Metab Dispos; 2006 Mar; 34(3):420-6. PubMed ID: 16381666
[TBL] [Abstract][Full Text] [Related]
7. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA
Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
12. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
13. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
[TBL] [Abstract][Full Text] [Related]
14. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Kinetic Characterization of Axitinib Metabolism.
Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ
Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
17. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
18. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
